Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

NDORMS has been designated a EULAR Centre of Excellence 2020-2025, in recognition of our continued high-quality research publications in rheumatology.

Two members of staff shake hands, celebrating that NDORMS has been named a European Centre of Excellence

EULAR, the European League Against Rheumatism, represents patients, health professionals and scientific societies of rheumatology of all European nations. It aims to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. 

EULAR Centres of Excellence are top rheumatology research units in Europe aiming to develop a group of first-class research centres for active researchers and enable exchange of fellows and research projects.

NDORMS, with the Botnar Research Centre and Kennedy Institute of Rheumatology, is one of the largest and most dynamic multidisciplinary academic rheumatology research centres in the world, with over 50 dedicated researchers focusing on rheumatic conditions.

We have one of the largest and broadest groupings of translational rheumatology research in the world; covering inflammatory, degenerative and congenital diseases of the musculoskeletal system. Scientific approaches include direct patient-focused research, epidemiology, and basic mechanistic research in immunology, genetics, bone, matrix and cartilage biology.

Professor Paul Bowness, Lead for the Oxford EULAR Centre of Excellence, said: “We are delighted with this award and the recognition it brings to our research in rheumatic conditions that affect the lives of millions of people around the world. We will continue our mission to develop and deliver excellent research to help patients now and in the future.”

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England